

Cover Story
By Matthew Bin Han Ong
The NCI-60, a panel of 60 cancer cell lines that have become the Rosetta Stone for the development of anticancer drugs, may be entering its twilight years as NCI develops new, and more expansive, patient-derived xenografts, or PDX models.
In Brief


Funding Opportunities
Drugs & Targets


Trending Stories
- Kennedy calls for a “moonshot” targeted on the role of the microbiome in cancer
- How City of Hope is turning microbiome science into better cancer care
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Charles Rudin named cancer center director at MSK
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - What are you reading in 2024?











